Sensus Healthcare, Inc. (SRTS): ANSOFF MATRIX [Dec-2025 Updated]

Look, you're trying to map out the next few years for Sensus Healthcare, Inc., and honestly, the landscape just got a lot clearer. With that massive $\mathbf{300\%}$ increase in SRT delivery code reimbursement from the new CMS codes, the domestic play is defintely set up for success-we saw a $\mathbf{20\%}$ sequential treatment volume jump in Q3 2025 alone. But that's just the start; this Ansoff Matrix shows Sensus Healthcare, Inc. isn't resting on its laurels, with plans to hit a $\mathbf{20\%}$ international revenue target and $\mathbf{\$24.5}$ million in cash ready for strategic M\&A moves. We've got clear, actionable paths here, from capitalizing on pent-up US demand to launching next-gen software and even eyeing adjacent markets; you'll want to see the specifics on how they plan to execute across all four quadrants below.

Sensus Healthcare, Inc. (SRTS) - Ansoff Matrix: Market Penetration

You're looking at how Sensus Healthcare, Inc. (SRTS) can sell more of its existing Superficial Radiotherapy (SRT) systems into its current US market. This is about maximizing the return on the technology you already have in the field and ready to ship.

The biggest lever right now is the new reimbursement certainty. The Centers for Medicare & Medicaid Services (CMS) finalized dedicated Current Procedural Terminology (CPT) codes for SRT in non-melanoma skin cancer. This move validates the technology and directly impacts the economics for providers.

Specifically, this change represents an increase in SRT delivery code reimbursement per fraction of more than 300% compared to the codes previously used. This leveling of the playing field between office-based reimbursement and hospital outpatient rates should significantly strengthen the Return on Investment (ROI) for dermatology offices and drive adoption.

To capitalize on this, Sensus Healthcare, Inc. (SRTS) has a ready supply to meet the expected surge in demand. The company exited Q3 2025 with nearly 100 SRT systems in inventory.

The existing Fair Deal Agreement (FDA) program is already showing strong utilization trends, which provides a solid base for market penetration efforts. Treatment volumes under the FDA program saw a 20% sequential treatment volume increase in Q3 2025 over Q2 2025, and a 52% increase compared to Q1 2025.

Here's a quick look at the Q3 2025 operational and financial context supporting this push:

The new distribution strategy is squarely aimed at a key segment of the US market. The strategic agreement with Radiology Oncology Systems (ROS) positions ROS as the primary distribution partner specifically to target hospital-based radiation oncology departments and freestanding oncology centers nationwide.

To drive patient awareness and convert the pent-up demand catalyzed by the new reimbursement codes, marketing efforts are being scaled up. The selling and marketing expense for Q3 2025 was reported at $2.2 million. To accelerate market penetration, this spend needs to be increased to boost patient awareness for SRT.

The immediate actions for market penetration focus on these key areas:

• Capitalize on the 300% reimbursement increase from new CMS codes.
• Convert the nearly 100 SRT systems in inventory into sales to meet US demand.
• Expand the Fair Deal Agreement (FDA) program, which saw a 20% sequential treatment volume increase in Q3 2025.
• Target hospital-based oncology departments via the ROS distribution partnership.
• Increase marketing spend, which was $2.2 million in Q3 2025, to boost patient awareness.

Finance: draft 13-week cash view by Friday.

Sensus Healthcare, Inc. (SRTS) - Ansoff Matrix: Market Development

The management target for Sensus Healthcare, Inc. is to achieve approximately 20% of total revenue from international sources within a 12-24 month timeframe. This goal is set against the backdrop of Q3 2025 revenue which totaled $6.88 million, or $6.9 million.

The foundation for this acceleration is the receipt of MDSAP (Medical Device Single Audit Program) certification for the entire superficial radiation therapy (SRT) product portfolio. This single audit compliance is designed to streamline regulatory efforts and expedite commercial deployment in key geographies.

The specific markets immediately accessible via the MDSAP certification include:

• - Canada (Health Canada)
• - Brazil (ANVISA)
• - Japan (PMDA)
• - Australia (TGA)

Sensus Healthcare, Inc. is actively expanding distribution channels, particularly in high-growth regions like China. For the third quarter of 2025, the company shipped three SRT systems to China. This follows the shipment of four units to China in the second quarter of 2025. The company exited Q3 2025 with $24.5 million in cash and no debt, positioning it to support this expansion while holding nearly 100 systems in inventory.

To map out the execution of this international push, here is a look at recent system shipments:

The strategy also involves establishing new commercial partnerships to secure future revenue streams from these new territories. This requires adapting marketing materials for the SRT-100 Vision, ensuring they address country-specific non-melanoma skin cancer treatment protocols.

Sensus Healthcare, Inc. is also actively working with potential commercial partners to lay the groundwork for additional revenue contributions from these new international areas.

Sensus Healthcare, Inc. (SRTS) - Ansoff Matrix: Product Development

You're looking at the core of Sensus Healthcare, Inc. (SRTS)'s future growth engine-new products and significant upgrades to existing ones. This is where the investment dollars are aimed to secure market share beyond the current base.

Finalize and launch the next-generation Sentinel 2.0 software platform to enhance recurring revenue from existing customers.

The commitment to enhancing recurring revenue streams is clear through the initiation of a multiphase R&D program for Sentinel 2.0. Initial results from this next-generation software platform are anticipated in 2026. This development is happening while the company is already seeing growth in treatment volume from existing Fair Deal Agreement (FDA) based SRT systems, which recorded a 27% sequential-quarter increase in FDA treatment volume in the second quarter of 2025.

Commercialize the pre-commercial TransDermal Infusion (TDI) product with Sentinel IT Solutions capabilities for existing dermatology practices.

The work-in-process TransDermal Infusion (TDI) product, which incorporates Sentinel™ IT Solutions capabilities, was showcased at the March 2025 American Academy of Dermatology Annual Meeting. This system is FDA-cleared for the local administration of ionic drug solutions. The Sentinel IT Solutions capabilities are already present in all six Sensus-branded aesthetic Smart Lasers.

Integrate the prototype handheld ultrasound device into the SRT-100 Vision workflow to improve lesion detection and practice efficiency.

Sensus Healthcare displayed a new prototype handheld ultrasound device at the March 2025 AAD meeting, specifically designed to help clinicians identify skin lesions and enhance practice efficiency. The existing SRT-100 Vision system already features integrated imaging and treatment planning capabilities, including High-Frequency Ultrasound for Image Guidance. The company is focused on streamlining the workflow, which the integration of imaging technology is intended to achieve, reducing treatment time.

Invest R&D funds, which were $4.1 million in the first half of 2025, into new SRT applications beyond NMSC and keloids.

The investment in future applications is substantial. Research and development expense for the first half of 2025 totaled $4.1 million, a significant step up from the $1.8 million spent in the first half of 2024. This spending supported the finalization of the TDI product and the R&D program for Sentinel 2.0. The company's strategy is to broaden its commercial footprint beyond the established uses of treating non-melanoma skin cancer (NMSC) and keloids.

Here's a quick look at the R&D spend progression:

The company is also positioning for broader market adoption, with CMS establishing dedicated CPT codes validating SRT for NMSC, which represents an increase in reimbursement per fraction of more than 300% compared with current codes.

Develop new aesthetic dermatology solutions to complement the existing Sensus Laser Systems portfolio.

The development efforts are aimed at expanding the total addressable market. The company's current aesthetic laser systems are already integrated with Sentinel IT Solutions capabilities. The TDI system itself is planned to be marketed to dermatologists for skin rejuvenation treatments, pre-laser treatments, and pre- and post-plastic surgery applications. The company affirms expectations to sign 3-5 additional multisite FDA customers this year. The long-term goal includes increasing international revenues to about 20% of total revenue within 12-24 months, up from the current 5-10% range.

The overall system sales goal is ambitious, targeting 1,000 global system sales in 2026.

• The TDI system is FDA-cleared for drug administration as an alternative to injections.
• The SRT-100 Vision is the only FDA-cleared IG-SRT system.
• The company shipped 21 SRT systems in Q1 2025.
• The company shipped 19 SRT systems in Q2 2025.
• The company shipped 16 SRT systems in Q3 2025.

Finance: draft 2026 system sales projection by Friday.

Sensus Healthcare, Inc. (SRTS) - Ansoff Matrix: Diversification

You're looking at the Diversification quadrant of the Ansoff Matrix for Sensus Healthcare, Inc. (SRTS), which means we're talking about entering entirely new markets with entirely new products. This is the highest-risk, highest-reward path, so we need to anchor these ideas to the hard numbers Sensus Healthcare, Inc. has right now.

The starting point for any aggressive move is the balance sheet. As of the third quarter of 2025, Sensus Healthcare, Inc. exited the quarter with $24.5 million in cash and reported no debt on its books. That's a clean $24.5 million war chest ready for deployment. For context, in the first quarter of 2025, the company strategically spent $2.6 million on Research and Development and $2.2 million on marketing, showing a capacity for significant cash deployment when necessary.

Here are the concrete diversification vectors Sensus Healthcare, Inc. could pursue, grounded in their current financial reality:

• - Acquire a company with established technology in a non-SRT, adjacent medical device market, like cryotherapy or photodynamic therapy.
• - Use the $24.5 million cash reserve to fund a strategic M&A move into a new, non-dermatology oncology segment.
• - Launch the Sensus Laser Systems portfolio into new international aesthetic markets not currently targeted by SRT distribution.
• - Develop a completely new, non-SRT diagnostic or therapeutic device for the primary care physician market in Europe.
• - Establish a joint venture with a large pharmaceutical company to develop a combination therapy involving SRT and a new topical drug.

Consider the international aesthetic play. Sensus Healthcare, Inc. shipped 16 Superficial Radiotherapy (SRT) systems in the third quarter of 2025, with three of those going internationally. This existing, albeit small, international footprint for SRT provides a distribution channel template. The Sensus Laser Systems portfolio, which addresses aesthetic needs like hair removal and skin toning, could piggyback on this nascent international structure, aiming to grow beyond the current base where Q3 2025 revenues hit $6.9 million.

The development of a completely new device for the European primary care market represents a long-term capital sink. This type of internal development must be weighed against the current profitability profile. For the third quarter of 2025, Sensus Healthcare, Inc. posted a net loss of $0.9 million. Funding a major new European device launch would require careful phasing to avoid deepening that quarterly loss significantly, especially when the trailing twelve-month revenue stands at $35.61 million.

Here's a quick look at the current operational scale versus the potential investment size for M&A:

Finally, a joint venture for combination therapy is a capital-light way to diversify the product offering. This strategy leverages the existing technology platform-the SRT systems-while adding a new revenue stream from a pharmaceutical partner's drug sales. The success of this venture would directly impact the top line, which saw $6.9 million in the last reported quarter.

Finance: draft 13-week cash view by Friday.